IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by IFP Advisors Inc

IFP Advisors Inc decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 45.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 603 shares of the medical research company’s stock after selling 508 shares during the quarter. IFP Advisors Inc’s holdings in IQVIA were worth $106,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. American National Bank & Trust purchased a new stake in shares of IQVIA in the first quarter worth about $26,000. Golden State Wealth Management LLC lifted its position in IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock worth $31,000 after acquiring an additional 130 shares in the last quarter. ST Germain D J Co. Inc. boosted its holdings in IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock worth $34,000 after acquiring an additional 76 shares during the period. GKV Capital Management Co. Inc. acquired a new stake in IQVIA in the fourth quarter valued at approximately $39,000. Finally, Larson Financial Group LLC lifted its position in shares of IQVIA by 109.9% during the first quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock worth $48,000 after purchasing an additional 144 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. UBS Group raised their target price on IQVIA from $185.00 to $225.00 and gave the company a “buy” rating in a research note on Wednesday, July 23rd. William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Redburn Partners set a $188.00 target price on IQVIA in a research report on Friday, May 23rd. Robert W. Baird increased their target price on IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a research note on Wednesday, July 23rd. Finally, Truist Financial lifted their price target on shares of IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a research note on Wednesday, July 23rd. Seven analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $228.62.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the business’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

IQVIA Stock Down 1.7%

IQV stock opened at $194.41 on Wednesday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The firm’s 50-day simple moving average is $159.17 and its 200 day simple moving average is $170.16. The stock has a market cap of $33.05 billion, a PE ratio of 28.13, a price-to-earnings-growth ratio of 2.17 and a beta of 1.30. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The company had revenue of $4.02 billion for the quarter, compared to analysts’ expectations of $3.96 billion. During the same quarter in the previous year, the company posted $2.64 earnings per share. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.